Abstract
Introduction: Although post-COVID-19 syndrome (PCS) with cognitive impairment is increasingly encountered in primary care, evidence-based recommendations for its appropriate management are lacking.
Methods: A systematic literature search evaluating the diagnosis and treatment of cognitive impairment associated with PCS was conducted. Practical recommendations for the management of PCS-associated cognitive impairment in primary care are summarized, based on an evaluation of pharmacological plausibility and clinical applications.
Results: Currently, the pathology of cognitive impairment associated with PCS remains unclear with no high-quality data to support targeted interventions. Existing treatment approaches are directed towards symptom relief where counseling on the chronicity of the disease and regular reassessments at 4- to 8-week intervals is considered reasonable. Patients should be informed and encouraged to adopt a healthy lifestyle that centers around balanced nutrition and appropriate physical activities. They may also benefit from the intake of vitamins, micronutrients, and probiotics. The administration of Ginkgo biloba extract could offer a safe and potentially beneficial treatment option. Other non-pharmacological measures include physiotherapy, digitally supported cognitive training, and, if indicated, ergotherapy or speech therapy. In most patients, symptoms improve within 8 weeks. If serious, ambiguous, or when new symptoms occur, specialized diagnostic measures such as comprehensive neurocognitive testing or neuroimaging should be initiated. Very few patients would require inpatient rehabilitation.
Conclusion: PCS with cognitive impairment is a debilitating condition that could affect daily functioning and reduce work productivity. Management in primary care should adopt a multidisciplinary approach, centering around physical, cognitive, and pharmacological therapies.
Introduction
The post-COVID-19 syndrome (PCS, also referred to as long-COVID) is defined by the absence of complete recovery after an acute episode of SARS-CoV-2 infection. According to the clinical case definition published by the World Health Organization (WHO), the post-COVID-19 condition occurs in individuals with a history of probable or confirmed SARS-CoV-2 infection usually 3 months from the onset of COVID-19, with symptoms lasting at least 2 months, and cannot be explained by an alternative diagnosis. Common symptoms include fatigue, shortness of breath, and cognitive dysfunction, which could impact on daily functioning (World Health Organization, 2021). However, there is no widely accepted definition of this condition (Sykes et al., 2021) to date. The prevalence of PCS is estimated at approximately 10% (Siso-Almirall et al., 2021; ) of patients infected with SARS-CoV-2, and especially higher among hospitalized patients with COVID-19 pneumonia in excess of 80% (). Although PCS can develop in patients of all ages, the highest percentage of diagnoses is observed in patients between 36 and 50 years of age, which could impact on work productivity through an increased absence from work (absenteeism) (). A 2021 retrospective cross-sectional study with 1,378 employees undergoing their annual medical check-up in Italy found that PCS was associated with reduced ability to work ().
In addition to fatigue, both cognitive impairment and memory complaints in previously cognitively healthy individuals are among the most prominent components in the neurological presentation of PCS. In patients who required hospitalization during SARS- CoV-2 infection, the prevalence of persistent cognitive impairment in the post-acute phase was reported to be 50%–65% (). According to a meta-analysis of 81 studies, more than one-fifth of patients reported cognitive impairment (). It is important to note that subjective cognitive dysfunction and objective findings of cognitive impairment post-COVID-19 may be incongruous.
Most patients with persistent symptoms following SARS-CoV-2 infection are managed within the primary care setting. A retrospective data analysis of 63 patients in the COVID-REHA outpatient clinic of the Medical University Hannover in Germany found that only 8% of patients underwent immediate inpatient rehabilitation after first diagnosis (Teixido et al., 2023). An online survey of 11 general practitioners (GPs) in Germany conducted between May and July 2021 revealed that each general practice treated an average of 12 patients with PCS at that time (). In a retrospective cohort analysis of data from health insurance claims for ambulatory care in Bavaria, Germany, between January 2020 and March 2022, 14.2% of patients with confirmed COVID-19 were diagnosed with PCS, and 6.7% received the diagnosis in at least two quarterly periods during a 2-year follow-up (). Although the management of PCS-associated cognitive impairment is of utmost importance in primary care, there are no evidence-based guidelines for diagnosis and therapy to date.
The aim of this scoping review was to provide an overview of literature references on PCS-associated cognitive impairment and to reflect the current research perspective. From the outcome combined with personal experience, we aimed to develop pragmatic recommendations with special emphasis on diagnosis and therapy in primary clinical care.
Materials and methods
A systematic literature search was conducted in PubMed (https://pubmed.ncbi.nlm.nih.gov), covering references published between 1 January 2020 and 7 March 2024 and reporting the management of cognitive impairment associated with PCS (search terms: post-COVID-19 syndrome OR post-acute COVID-19 syndrome OR post-COVID OR long-COVID OR post-COVID-19 condition OR post-acute sequelae of COVID-19 infection OR long-haul COVID OR PSC AND cognitive impairment). By means of additional filters implemented in the PubMed database for the research field COVID-19, the records were further selected electronically for diagnosis (broad scope) and therapy (broad scope). The results were further restricted to English and German language. In addition, a manual search was carried out in the literature known to the authors. The information derived from the publications was summarized and analyzed descriptively.
Key topics of this scoping review include the diagnosis of cognitive impairment associated with PCS and the follow-up of therapeutic outcomes. We thus reviewed publications on cognitive tests, including their sensitivity and specificity for PCS based on published clinical studies, as well as their suitability for the primary care setting.
Results
As illustrated in the flow diagram (Figure 1), our literature search resulted in 867 hits. Of these, a total of nine scientific publications were considered as relevant for therapy and 44 for diagnosis of PCS-associated cognitive impairment. Two other publications retrieved by hand search, i.e., the German S1 guideline on long/post-COVID () and recommendations for an interdisciplinary and multimodal practical approach for PCS (Teixido et al., 2023), were also included.
FIGURE 1
Pathogenesis of cognitive impairment associated with PCS
The pathophysiology underlying PCS remains unclear. Hypotheses on pathogenic mechanisms implicate both systemic effects and sequelae from acute SARS-CoV-2 organ injury. Hyperinflammation (), abnormal immunological response and autoimmunity (), viral persistence (Sherif et al., 2023), reactivation of latent Epstein-Barr virus (Su et al., 2022), microvascular dysfunction (), as well as coagulopathies and endotheliopathy () have been suggested in the etiopathogenesis of PCS.
Specific pathogenic mechanisms involved in COVID-19-associated cognitive impairment are also not fully understood. The three main factors identified by recent literature reviews (Yang et al., 2021; ), i.e., neuroinflammation, neurovascular dysfunction, and disruption of cellular energy metabolism, are summarized below. Several other mechanisms are currently being researched, e.g., microbial dysbiosis (), adverse effects of the viral spike protein on the angiotensin-converting enzyme two receptor, or inhibition of the gamma-aminobutyric acid (GABA) receptors ().
Neuroinflammation
As shown by viral detection in the cerebrospinal fluid in some patients, SARS-CoV-2 is neuroinvasive and may spread through various pathways into the central nervous system (Song et al., 2021). This has been suggested to trigger neuroinflammation (), which may account for neurotoxicity and neuronal damage. Microglia, the resident mononuclear immune cells of the central nervous system (CNS), play an essential role in the response to neuroinflammation. Activated microglia cells in the white matter of the brain further amplify neuroinflammation and can be associated with brain tissue damage (). Furthermore, the generation of autoantibodies has a negative impact on neurogenesis and neuronal repair ().
Neurovascular dysfunction
Microvascular injury and endothelial damage can trigger excessive thrombin production and inhibit fibrinolysis that leads to formation of microthrombi. These pathogenetic factors may cause hypoperfusion and oxidative stress (). In a prospective observational cohort study, prolonged endothelial dysfunction with impairments of the microcirculation was observed and may explain ongoing symptoms in PCS ().
Disruption of cellular energy metabolism
Mitochondrial dysfunction, possibly caused by oxidative stress, leads to systemic reduction of metabolic activity and cellular bioenergetics within the CNS structures, which adversely affects neuronal function (; ).
Diagnostic recommendations
To date, no clear diagnostic criteria or biological markers for PCS have been established. Unless there are warning signs, diagnostics should be handled within the primary care setting. The steps described below have been recommended in a guideline () and are based on clinical experience. An algorithm for pragmatic management of individuals with cognitive impairment associated with post-COVID syndrome in primary care is also depicted in Figure 2.
FIGURE 2
History of COVID-19 infection
Firstly, the preceding SARS-CoV-2 infection should be confirmed in patients’ medical history, ideally by polymerase chain reaction (PCR) or by a positive antigen test, even if asymptomatic. In primary care, this should be documented in the relevant patient files. The severity of the preceding infection has relevance for the individual prognosis and can be classified by means of WHO criteria. If patients report cognitive complaints, they should be asked about the onset of symptoms and whether complaints are related to PCS or may have another cause.
Physical examination
Physical examinations should be tailored to the specific concerns of patients, but should also include assessment of the cardiovascular system and a neurological examination. To assess functional status, the 1-min sit-to-stand test can be used, with the patient sitting down and standing up as often as possible within 1 minute. Depending on their age group, women can perform an average of 27–40 repeats per minute and men 30–45 repeats per minute. Lower values may indicate a reduced physical performance, which then should be examined further. Handgrip strength was shown to be a good indicator for fatigue. It requires a dynamometer and an accurate and standardized conduct.
Laboratory tests
Blood tests should be performed routinely and include heart, liver, and kidney function parameters. Furthermore, inflammatory markers, i.e., primarily C-reactive protein, immunological parameters, and blood coagulation parameters, should be determined. Testing for COVID-infection markers must be decided case by case, e.g., to exclude an acute infection. In PCS, tests for SARS-CoV-2 have often turned negative when the patient presents.
Tests of cognitive functioning
Most of the objective cognitive tests applied in clinical studies of PCS were developed in the context of dementia research. As can be seen from the literature found, the domains of cognition that are most frequently impaired in the case of PCS are executive functioning (; ; ; Serrano-Castro et al., 2022; Shanley et al., 2022; ; ; ; ; ; Taruffi et al., 2023), attention (; ; ; Serrano-Castro et al., 2022; ; ; ; ), and delayed recall (; ; ; Serrano-Castro et al., 2022; Shanley et al., 2022). Notably, up to two-thirds of patients with subjective cognitive impairment due to PCS still pass these tests successfully, either in the total scores or in single domains (), which shows the limitations of using these cognitive tests in this patient group. Nevertheless, reliable, short, and easy-to-perform cognitive tests such as the Montreal Cognitive Assessment (MoCA), the Mini-Mental State Examination (MMSE), or the Demenz-Detektion (DemTect) are useful in primary care, especially if their conduct can be delegated to the nursing staff.
Since there is no specific test for PCS-associated cognitive impairment, the MoCA or the MMSE are recommended as global screening tools (). In 19 of the 44 included studies, the MoCA was applied as an outcome criterion (). Twelve of the studies applied the MMSE. In studies where both tests were applied, the MMSE tended to be less sensitive than the MoCA (; ). Overall, although there are concerns that it may not be sensitive enough to reliably detect mild impairment or impairment in single domains of cognition, MoCA appears to be the most used tool (). Noteworthy, a positive screening result may indicate a severe course or a comorbid condition requiring special attention while a negative result does not exclude mild cognitive deficits.
Patient self-assessment tools can be used both to identify cognitive impairment and for follow-up (). The German S1 guideline on long/post-COVID () recommends the abbreviated Measurement of Everyday Cognition (ECog12), which is an assessment tool for self-reported cognitive decline. Another self-assessment tool is the Clinical Global Impression Scale which offers an alternative in terms of a robust measure assessing the global improvement of a patient’s condition. It can be applied to cognition and memory by asking the patient to score from 1 = ‘very much improved’ to 7 = ‘very much worse’. Finally, the five-item version of the Perceived Deficits Questionnaire may be used (Walker et al., 2023), which contains five simple cognition-related questions related to the previous week that are answered by the patients by means of a scale ranging from ‘never’ to ‘almost always’.
Imaging procedures
In eight studies relating to diagnosis of PCS, imaging procedures such as magnetic resonance imaging (MRI) or computed tomography (CT) were most frequently reported. In a retrospective analysis of case files from 243 patients, 37% were referred for neuroradiological examinations, 31% for electroencephalogram (EEG), and 28% for color Doppler of blood vessels of the head and neck. The results of the tests were not stated ().
In five studies with patient numbers ranging from 12 to 156, MRI scans of the brain (; ; ; Taruffi et al., 2023), or MRI or CT () did not reveal specific pathological findings correlating with cognitive impairment.
From another study including 86 patients with subjective PCS and 36 healthy controls, persistent structural and functional brain abnormalities following MRI examination 11 months after the acute infection were reported (). Bilateral hypometabolism of regions of cerebrum and cerebellum associated with cognitive impairment was detected by positron emission tomography (PET) scan () even 1 year after COVID-19 infection ().
Differential diagnosis
Differential diagnosis is of utmost importance to ensure that cognitive impairment has not been present before the acute phase of COVID-19. The patient, or a caregiver, should be asked since when cognitive problems have existed. Primary care physicians usually have an advantage of knowing the patient’s medical history and thus do not have to rely solely on the patient’s own assessment.
Results from a qualitative study conducted in Germany in primary care provided some insights into how GPs managed patients with PCS (). The exclusion of other underlying conditions, such as hypothyroidism, and other neurologic-psychiatric conditions such as depression, dementia, stroke, or encephalopathy was the most common diagnostic approach.
Therapeutic recommendations
Since most patients present with moderate or mild symptoms in primary care, a conservative approach including non-pharmacological and pharmacological measures is suitable (Figure 2). According to a practice-based recommendation based on experiences at the COVID-rehabilitation ambulance (Teixido et al., 2023), this includes counseling or coaching of patients and addressing their individual concerns. Besides the restitution of health and capabilities to carry out daily activities, maintaining or regaining the ability to work is of major importance for many patients. They should therefore be informed that complaints due to PCS are mostly reversible within several weeks or months, and usually disappear without any sequelae. It is important for patients to accept that they have to give themselves time for recovery (). Granting sufficiently long sick leave is therefore reasonable in most cases. In a recent study, guided qualitative interviews were conducted with 25 people with PCS (). Results showed that many interviewees reached their stress limit during routine household activities or childcare. Of the 25 participants, 19 experienced limitations in pursuing leisure activities, and 10 of those 23 interviewees with jobs reported being on sick leave for several months. Returning to work is possible if daily activities are manageable and 500 m can be walked symptom-free. Work intensity should be discussed with the employer and other restrictions may apply, e.g., avoiding night shifts (). Moreover, physicians should discuss with their patients if their cognitive impairment may be a safety issue for professional or leisure activities, particularly for driving or operating machinery.
Follow-up visits at 4- to 8-week intervals are considered appropriate. If patients present with serious, unclear, suddenly evolving symptoms, poor general condition, or other warning signs such as disorientation and confusion, referrals to specialized care are indicated. However, sometimes there are waiting times, particularly for psychotherapy or inpatient rehabilitation.
Non-pharmacological interventions
General recommendations for patients with cognitive impairment associated with PCS include counseling on lifestyle factors such as improving sleep, reducing stress, adopting a healthy diet, and stopping smoking. A healthy diet consists of ample portions of fruits and salad, prioritizing freshly cooked meals, and reducing meat consumption (). Physical activity plays a crucial role in reducing the impact of PCS and engagement in exercise two to three times a week is recommended (). However, setting realistic and achievable goals and avoiding overexertion is of great importance.
Excessive body weight has been identified as a prognostic factor for poor outcomes of COVID-19. Obesity is likely to impair immune response to viral infections, leading to the development of a chronic low-grade inflammatory state and an elevated level of oxidative stress. Hence, body weight reduction may potentially have a positive effect in obese patients with PCS. In this context, there is ongoing discussion regarding the use of ketogenic diets, which are high-fat diets characterized by a marked carbohydrate restriction. It is important to note that particularly very low-calorie ketogenic diets should be supervised by professionals (). Implementation of weight reduction training aligns with the goal of strengthening muscles by exercise to improve PCS symptoms and has been found beneficial (; ).
Behavioral interventions mentioned by Müller and Di Benedetto () comprise mind-body interventions, musical therapy, and meditation. These interventions, which are of low to moderate cost, can be conducted as self-practice at home and can alleviate symptoms of PCS. On a biochemical level, meditation is associated with a release of anti-inflammatory cytokines, modulation of neuroimmune responses, and decrease in C-reactive protein levels.
A practical guideline on PCS including cognitive impairment recommends various non-pharmacological therapeutic measures including digital solutions for cognition or memory training (Teixido et al., 2023). Some of them are freely available on the internet (e.g., for German-speaking patients: https://www.mental-aktiv.de/uebungen-klassisch/) or as YouTube videos with brain training exercises. Others can be prescribed by physicians, e.g., the App NeuroNation MED as digital health application (Digitale Gesundheitsanwendung, DiGA) in Germany. A currently ongoing study is evaluating the efficacy of computer-aided cognitive training in adult patients with PCS (ClinicalTrials.gov ID NCT05338749). Despite the pending results, this study presents an interesting approach to use game-based computer-delivered cognitive training to address mental symptoms such as attention, memory, or deficits in executive functions.
Further elements of outpatient rehabilitation may be physiotherapy, physical rehabilitation, or special fitness measures (Teixido et al., 2023). The RECOVE trial evaluated the effectiveness of exercise and respiratory muscle training administered in outpatient settings for patients with PCS. The authors found that exercises based on concurrent training (including supervised resistance and endurance exercises of low-to-moderate intensity) and concurrent training combined with inspiratory muscle training significantly alleviated dyspnea and fatigue, as well as enhanced overall health status ().
In specific circumstances, ergotherapy and speech therapy may be recommended. The latter may be necessary if given cognitive communication problems lead to the impairment of language fluency.
Nutraceuticals
Vitamins
The authors of a review article concluded that high-dose intravenous vitamin C (3.5 g–75 g daily) might be a reasonable treatment option for PCS, due to its antioxidant, anti-inflammatory, endothelial-restoring, and immunomodulatory effects (Vollbracht and Kraft, 2021).
Although almost all PCS patients experience vitamin D deficiency, no correlation was found between vitamin D levels and severity of PCS symptoms (). Nevertheless, supplementation of 2,000 IU daily is recommended for patients with vitamin D blood levels below 30 ng/mL (Vieth, 2022).
Vitamins of the B complex are beneficial for the nervous and the immune system. Anecdotal evidence suggests that low-dose vitamin B supplementation (10 mg thiamine, 4 mg riboflavin, 40 mg nicotinamide, 6 mg dexpanthenol daily) improved COVID-19 mortality (). Dosage recommendations for folic acid supplementation specifically for PSC were not found in the literature. As a general recommendation, vitamins of the B complex should be supplemented unless the blood levels are at the upper limit of the normal range.
Micronutrients
Micronutrients, including selenium, iron, zinc, and magnesium, are also critical for proper functioning of the immune system. Although there is no evidence for a general benefit in PCS patients, daily supplementation with 35–40 µg selenium, 15 mg iron, 15 mg zinc, or 350 mg magnesium daily can be considered in cases where a deficiency of these nutrients is present (Tosato et al., 2022; ).
Pre- or probiotics
A persisting reduction in the richness of normal composition of gut microbiota can be found even 6 months after recovering from COVID-19 infection. Although controlled clinical trials focusing on patients with PCS are currently lacking, the use of probiotics and prebiotics may be considered as a supportive measure (). Additionally, immunomodulatory effects of probiotics may help in restoring the gut microbiome altered during viral infections ().
Pharmacological treatments
To date, the pathologic mechanisms of cognitive impairment associated with PCS are unclear and no evidence-based treatments are available (). Thus, management is currently focused on symptomatic treatment including anti-inflammatory drugs such as corticosteroids, anticoagulants, or analgesics, if indicated. The following treatment option specific for cognitive impairment was selected from the literature search based on empirical pharmacological plausibility. Due to the lack of rigorously controlled clinical trials, a favorable safety profile is of high importance.
Ginkgo biloba extract
Most published nonclinical and clinical studies investigating Ginkgo biloba extract were done using the proprietary Ginkgo biloba leaves extract EGb 761®. EGb 761® was shown to display multimodal effects on a variety of pathogenetic processes which may be involved in PCS (). Flavonoids, terpenoids, and anthocyanidins exhibit neuroprotective effects by modulating signaling pathways known to be impacted by COVID-19 (Zaa et al., 2023). They have been shown to inhibit neuroinflammation by reducing inflammatory activation in microglia cells (). Importantly, it protects the function of endothelial cells (; Zhang et al., 2017) and improves brain and sensory organ perfusion by reducing blood viscosity (). Randomized controlled trials demonstrated the efficacy of Ginkgo extract at the dose of 240 mg daily in mild cognitive impairment (; ). A meta-analysis of seven randomized, placebo-controlled trials in patients with dementia showed that treatment-associated risks (relative risk of adverse events, rates of premature withdrawal) in patients taking EGb 761® did not differ noticeably compared to the placebo group and confirmed the safety and tolerability of this extract (). However, even if these pharmacological and clinical results are promising, the available data are still preliminary and require additional proof by further studies ().
In patients with cognitive impairment, treatment with Ginkgo extract can be started immediately at first consultation. Follow-up is recommended after 8 weeks of treatment. In a small case series with five patients aged 26–59 years and suffering from concentration and attention deficits, cognitive deficiencies, and/or fatigue, cognitive deficits and other symptoms, such as fatigue and hyposmia, were substantially improved or completely restored by treatment with EGb 761® within 6 months (Zifko et al., 2022). The authors therefore recommended randomized controlled clinical trials to be conducted in order to confirm efficacy in this indication.
Research perspectives for the management of cognitive impairment associated with PCS
Our literature search revealed nine publications on experimental studies investigating therapeutic approaches. Table 1 presents an overview of study methodologies and main outcomes Table 2. Out of the studies found, only three were small scale randomized controlled studies. Each one was a controlled study on the efficacy of the H2 antagonist famotidine () or donezepil hydrochloride (), and one investigated the effectiveness of a neuro-meditation program (). A case control study evaluated the efficacy of cognitive remediation therapy (), a feasibility pilot study was carried out on a personalized computerized cognitive training (), and one observational pilot study evaluated a multimodal therapy concept with behavioral therapy-oriented, disorder-specific psychotherapy and exercise therapy (). Moreover, a retrospective analysis was performed with data from 64 patients suffering from PCS who were treated with a day-by-day individualized psychological intervention of cognitive stimulation in addition to a standard in-hospital rehabilitation program (). A case series with 23 outpatients investigated the effect of transcranial magnetic stimulation () and another case series reported on five patients treated with EGb 761® following presentation with concentration and attention deficits, cognitive deficiencies, and/or fatigue 9–35 weeks after COVID-19 infection (Zifko et al., 2022).
TABLE 1
| References | Methodology | Intervention duration | Inclusion criteria | Primary outcomes |
|---|---|---|---|---|
| Randomized, controlled study | 5 mg donepezil hydrochloride daily (n = 10) or placebo (n = 15) | Patients with post-COVID memory impairment and a history of hospitalization | The statistical analysis revealed no significant difference in Wechsler Memory Scale-Revised test WMS-R the drug and control groups at the 4-week and 12-week follow-up periods | |
| 12 weeks | ||||
| Randomized, double-blind, placebo controlled study | 40 mg famotidine (n = 29) twice daily or placebo (n = 29) | Patients aged 18–65 years with confirmed diagnosis of COVID-19 and Score ≤23 on the Mini-Mental State Examination (MMSE) test or a score ≤22 on the Montreal Cognitive Assessment (MoCA) | The mean difference of the MMSE score of the patients in the famotidine group was significantly higher at week 6 (1.28 (95% CI 0.28–2.28), p-value = 0.014)) and at week 12 (2.44 (95% CI 1.47–3.41), p-value < 0.001)) compared to those in the placebo group | |
| 12 weeks | ||||
| Randomized controlled study | Sound therapy and coach-guided meditation associated with light stimulations (n = 17) versus no therapy in control group (n = 17) and healthy participants (n = 15) | Patients older than 18 with long COVID (n = 34) | Improvement of cognitive functioning shown by cognitive tests (Choice Response Time, Pattern Comparison Task, Simon Task, Pursuit Rotor Task, Corsi Block-Tapping Task) | |
| 5 weeks | Healthy participants (n = 15) | |||
| Case control study as proof-of-concept study | Cognitive remediation therapy (n = 15) versus no therapy (n = 30) | COVID-19 survivors presenting cognitive impairments at 1-month follow-up | Mixed model ANOVA revealed a significant effect over time of the cognitive remediation therapy programme on global cognitive functioning (F = 4.56, p = 0.039), while no significant effect was observed in the untreated group | |
| 2 months | ||||
| Feasibility Pilot Study with single treatment arm | At least 10 sessions of a self-administered computerized cognitive training with gamified cognitive tasks (n = 73) | Self-reported cognitive dysfunction more than 3 months after a diagnosis of COVID-19 | Most of the participants obtained higher scores after computerized cognitive training in each of the domains as compared with baseline | |
| 8 weeks | ||||
| Case documentation | Multimodal therapy concept with behavioural therapy-oriented, disorder-specific psychotherapy and exercise therapy (n = 30) | Patients with post Covid referred to rehabiliation | Positive feed-back of participants on multimodal treatment approach | |
| Observational study | Individualized psychological intervention of cognitive stimulation (45 min) in addition to a standard in-hospital rehabilitation program (n = 64) | Patients with post-acute SARS-CoV-2 cognitive impairment (brain fog) | A significant improvement in the MoCA score was found between admission and discharge (20.4 ± 5vs. 24.7 ± 3.7; p < 0.0001) | |
| Real word research, case series | 20 sessions of transcranial magnetic stimulation treatment (n = 23) | Outpatients with chronic fatigue (n = 12) and cognitive dysfunction (n = 11) associated with long-COVID | The score on the Perceived Deficits Questionnaire–Depression 5-item, which reflects cognitive function, improved from 10.0 to 6.3 | |
| 20 days | ||||
| Zifko et al. (2022) | Case series | 160 mg EGb 761® daily | 5 Patients who presented with concentration and attention deficits, cognitive deficiencies, and/or fatigue 9–35 weeks after infection | EGb 761® might be a low-risk treatment option for post-COVID-19 patients with cognitive symptoms |
| 6–14 weeks |
Data collections on therapy of cognitive impairment associated with PCS.
TABLE 2
| Score | Definition |
|---|---|
| 0 | No clinical or neurolgical evidence of infection |
| 1 | Ambulatory treatment, no limitation of activities |
| 2 | Ambulatory treatment, limitation of activities |
| 3 | Hospitalized, no oxygen therapy |
| 4 | Hospitalized, oxygen mask or nasal prongs |
| 5 | Hospitalized, noninvasive mechanical ventilation or high-flow nasal cannula |
| 6 | Hospitalized, intubation and invasive mechanical ventilation |
| 7 | Hospitalized, invasive mechanical ventilation and additional support such as pressors or extracardiac membranous oxygenation |
| 8 | Death |
nine-point WHO ordinal clinical severity scale for COVID-19.
In August 2023, the US National Library of Medicine of the National Institutes of Health (NIH) clinical research registry (www.clinicaltrials.gov) reported 28 clinical trials investigating treatments of cognitive impairment associated with PCS. Of these, 18 clinical trials investigated various non-pharmacological interventions (ranging from Tai Chi, psychoeducation to computer-based cognitive trainings) and 10 investigated pharmacological treatments (atorvastatin, the NMDA receptor antagonist DAOIB, the antidepressant vortioxetine, an amniotic fluid product VIX001 for intravenous injection, ketamine (CI-581a and b) as glutamatergic modulator, as well as medium chain triglycerides, safflower oil, or nicotinamide riboside as dietary supplements).
Discussion
PCS-associated cognitive impairment as complication after acute SARS-CoV-2 infection has a negative impact on daily functioning and quality of life and leads to loss of working days or reduced productivity at work and to increased use of healthcare resources. Most patients are managed in a primary care setting requiring a multifactorial and/or multidisciplinary approach with longitudinal follow-up (Siso-Almirall et al., 2021). For cognitive impairment associated with PCS, there are neither clinical guidelines nor well designed randomized controlled trials providing an evidence base for diagnostics and therapy so far. When considering the body of evidence, GPs may feel that they lack sufficient knowledge on this topic. Nevertheless, it is crucial for the healthcare system that only patients requiring secondary or tertiary care are referred to specialists, especially as waiting times amount to several weeks or even months in some countries.
This scoping review provides an overview of literature references on PCS-associated cognitive impairment and develops pragmatic recommendations with special emphasis on diagnosis and therapy in primary clinical care. A similar review of PCS by Nicotra et al. was recently published (), which did, however, not focus on primary care. The systematic search resulted in 947 unique records available until May 2023, from which 180 studies were retrieved. The authors stated that only a minority of studies included patients according to stringent temporal criteria for syndrome onset (34%), while most studies reported a required minimum duration of symptoms (77%). In our search, we applied the filters of the literature database for diagnosis and thereby identified 44 clinical studies that applied cognitive tests or imaging procedures (mostly MRI). Nicotra et al. found 36 studies which employed cognitive measures: screening tests alone (n = 19), full neuropsychological batteries (n = 25), or both (n = 29), while 30 studies performed psychiatric testing (). Although the numbers vary, the conclusions of the systematic searches are similar. Nicotra et al. reported that cognitive deficits were documented in 39% of subjects, the most frequently affected domains being attention/executive functions (90%) and memory (67%). In our review, only a few individual tests reached positive results in more than 50% of participants. In patients reporting subjective cognitive complaints, measurement based on objective criteria is challenging due to the fact that only half of the patients respond to cognitive tests. In research settings, the conduct of cognitive test batteries is recommended for diagnosis of PCS-associated cognitive impairment. This is time-consuming and not practicable under the conditions of primary care. Since many patients suffer from fatigue, a complete test battery may be too strenuous and is therefore not feasible. Screening tools developed for dementia such as MoCA or MMSE are not sensitive enough for this patient group but are nevertheless useful to identify patients with severe cognitive impairment for whom specialist care is necessary.
Currently, there are many ongoing research activities and clinical studies evaluating PCS. Since there is no uniform definition of the disease, the results are sometimes difficult to interpret. So far, no clearly defined anatomical equivalents or biomarkers for the condition have been found. It seems that most research teams did not find characteristic features in imaging procedures, although this is still an important step in excluding other causes. Moreover, tools for the measurement of cognitive impairment applied in clinical studies are heterogenous and results are therefore not transferrable. The diagnosis or inclusion of patients in almost all studies published relies on self-assessment of patients. All these factors may explain why the results of different studies are equivocal. However, due to the great burden of PCS on the healthcare system, research on the pathogenesis, diagnosis, and therapy is needed. Harmonized methodological approaches are required for future research.
Factors influencing cognitive disturbances in PCS are currently being researched, but the pathogenesis is still not elucidated. Therefore, it is not possible to develop causative drugs that target the condition. Our literature search retrieved only very few publications on clinical studies investigating non-pharmacological or individual pharmacological therapeutic approaches. This is not surprising, given that PCS is a relatively new disease and many studies are therefore still ongoing, as shown by our search in the NIH clinical research registry. While some studies specific to the treatment of PSC-associated cognitive impairment have been published, no confirmatory clinical trials on the efficacy of treatment options or proven therapeutic strategies are available (). This is due to the relatively new disease and to the fact that there still is a lack of data on the underlying pathophysiological mechanisms. Further research in both fields is therefore needed.
A conservative approach is recommended in primary care unless warning signs such as poor general condition or sudden onset of severe symptoms appear. Pragmatic management strategies consist of a multidisciplinary approach tailored for the individual patient involving counseling on the nature of the disease, optimal lifestyle, digital cognitive training, and non-pharmacological as well as pharmacological therapies.
If indicated, physiotherapy, ergotherapy, or speech therapy can be implemented. Neurocognitive rehabilitation should only be initiated in serious cases, with support from social services (). These recommendations may help to allocate resources more efficiently.
Due to its potent anti-inflammatory properties, enhancement of neuroplasticity, and well-proven clinical efficacy, EGb 761® may be beneficial for use in patients with cognitive impairment associated with PCS. In a case series involving patients who experienced persistent cognitive symptoms following SARS-CoV-2 infection, treatment with EGb 761® improved or eliminated cognitive deficits (Zifko et al., 2022). The favorable safety and tolerability profile of EGb 761® supports its use additionally (Schulz et al., 2018). Thus, EGb 761® might be a low-risk treatment option for cognitive impairment associated with PCS.
Symptomatic treatment may include the supplementation of vitamin B complex, vitamin D and micronutrients. Vitamin C may be beneficial due to its antioxidant effect and probiotics have been shown to improve dysbiosis and thereby support the immune system.
Our scoping review may be limited by the fact that no systematic data extraction was carried out and the selection of reports was rather based on subjective assessment of their relevance. Since personal experiences can vary and may not be representative of the broader clinical landscape, the conclusions drawn in our work could be subject to a certain bias. Like all expert recommendations, our findings therefore represent the lowest level of evidence. Nevertheless, we provide a comprehensive overview and analysis of the huge amount of published literature, which might be helpful and time-saving in clinical practice. To our knowledge, this is the first review focusing on primary care as well as on cognitive sequels. Our work also shows that further research is urgently needed to develop evidence-based treatments.
Statements
Author contributions
UZ: Conceptualization, Data curation, Visualization, Writing–review and editing. KG: Conceptualization, Data curation, Visualization, Writing–review and editing. RS: Conceptualization, Data curation, Visualization, Writing–review and editing. SK: Conceptualization, Data curation, Visualization, Writing–review and editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article.
Acknowledgments
We thank Małgorzata Biernikiewicz and Patricia Buchholz of Valid Insight, Macclesfield, United Kingdom for providing medical writing support. These Medical writing services were funded by Dr. Willmar Schwabe.
Conflict of interest
This research received funding from Dr. Willmar Schwabe GmbH & Co. KG. The funder was involved in the study design and data collection. The final decision to submit the article for publication remained with the authors.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AielloE. N.FiabaneE.ManeraM. R.RadiciA.GrossiF.OttonelloM.et al (2022). Screening for cognitive sequelae of SARS-CoV-2 infection: a comparison between the mini-mental state examination (MMSE) and the Montreal cognitive assessment (MoCA). Neurol. Sci.43 (1), 81–84. 10.1007/s10072-021-05630-3
2
AiyegbusiO. L.HughesS. E.TurnerG.RiveraS. C.McMullanC.ChandanJ. S.et al (2021). Symptoms, complications and management of long COVID: a review. J. R. Soc. Med.114 (9), 428–442. 10.1177/01410768211032850
3
AstinR.BanerjeeA.BakerM. R.DaniM.FordE.HullJ. H.et al (2023). Long COVID: mechanisms, risk factors and recovery. Exp. Physiol.108 (1), 12–27. 10.1113/EP090802
4
BachmeierB. E.HolzleS.GasserM.van den AkkerM. (2023). How do German general practitioners manage long-/post-COVID? A qualitative study in primary care. Viruses15 (4), 1016. 10.3390/v15041016
5
BarreaL.VetraniC.CaprioM.CataldiM.GhochM. E.ElceA.et al (2022). From the ketogenic diet to the mediterranean diet: the potential dietary therapy in patients with obesity after CoVID-19 infection (post CoVID syndrome). Curr. Obes. Rep.11 (3), 144–165. 10.1007/s13679-022-00475-z
6
BonillaH.PelusoM. J.RodgersK.AbergJ. A.PattersonT. F.TamburroR.et al (2023). Therapeutic trials for long COVID-19: a call to action from the interventions taskforce of the RECOVER initiative. Front. Immunol.14, 1129459. 10.3389/fimmu.2023.1129459
7
CalabriaM.Garcia-SanchezC.GrundenN.PonsC.ArroyoJ. A.Gomez-AnsonB.et al (2022). Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms. J. Neurol.269 (8), 3990–3999. 10.1007/s00415-022-11141-8
8
CarfiA.BernabeiR.LandiF.Gemelli AgainstC.-P.-A. C. S. G. (2020). Persistent symptoms in patients after acute COVID-19. JAMA324 (6), 603–605. 10.1001/jama.2020.12603
9
Castanares-ZapateroD.ChalonP.KohnL.DauvrinM.DetollenaereJ.Maertens de NoordhoutC.et al (2022). Pathophysiology and mechanism of long COVID: a comprehensive review. Ann. Med.54 (1), 1473–1487. 10.1080/07853890.2022.2076901
10
CatalanoA.IacopettaD.CeramellaJ.MaioA. C.BasileG.GiuzioF.et al (2022). Are nutraceuticals effective in COVID-19 and post-COVID prevention and treatment?Foods11 (18), 2884. 10.3390/foods11182884
11
CebanF.LingS.LuiL. M. W.LeeY.GillH.TeopizK. M.et al (2022). Fatigue and cognitive impairment in Post-COVID-19 Syndrome: a systematic review and meta-analysis. Brain Behav. Immun.101, 93–135. 10.1016/j.bbi.2021.12.020
12
CrivelliL.CalandriI.CorvalanN.CarelloM. A.KellerG.MartinezC.et al (2022). Cognitive consequences of COVID-19: results of a cohort study from South America. Arq. Neuropsiquiatr.80 (3), 240–247. 10.1590/0004-282X-ANP-2021-0320
13
DavisH. E.McCorkellL.VogelJ. M.TopolE. J. (2023). Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol.21 (3), 133–146. 10.1038/s41579-022-00846-2
14
Diez-CirardaM.YusM.Gomez-RuizN.PoliduraC.Gil-MartinezL.Delgado-AlonsoC.et al (2023). Multimodal neuroimaging in post-COVID syndrome and correlation with cognition. Brain146 (5), 2142–2152. 10.1093/brain/awac384
15
DonnachieE.HapfelmeierA.LindeK.TauscherM.GerlachR.GreisselA.et al (2022). Incidence of post-COVID syndrome and associated symptoms in outpatient care in Bavaria, Germany: a retrospective cohort study using routinely collected claims data. BMJ Open12 (9), e064979. 10.1136/bmjopen-2022-064979
16
DunabeitiaJ. A.MeraF.BaroO.Jadad-GarciaT.JadadA. R. (2023). Personalized computerized training for cognitive dysfunction after COVID-19: a before-and-after feasibility pilot study. Int. J. Environ. Res. Public Health20 (4), 3100. 10.3390/ijerph20043100
17
Elizalde-DiazJ. P.Miranda-NarvaezC. L.Martinez-LazcanoJ. C.Martinez-MartinezE. (2022). The relationship between chronic immune response and neurodegenerative damage in long COVID-19. Front. Immunol.13, 1039427. 10.3389/fimmu.2022.1039427
18
ErdinҫlerD. S.KarakoҫY.ToplanS.ÖnenS.SukyasyanA.BeğerT.et al (1996). The effect of ginkgo biloba glycoside on the blood viscosity and erythrocyte deformability. Clin. Hemorheol.16 (3), 271–276. 10.3233/ch-1996-16306
19
Fernandez-CastanedaA.LuP.GeraghtyA. C.SongE.LeeM. H.WoodJ.et al (2022). Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation. Cell185 (14), 2452–2468.e16. 10.1016/j.cell.2022.06.008
20
FerrucciR.CuffaroL.CapozzaA.RosciC.MaioranaN.GroppoE.et al (2023). Brain positron emission tomography (PET) and cognitive abnormalities one year after COVID-19. J. Neurol.270 (4), 1823–1834. 10.1007/s00415-022-11543-8
21
FrankeC.BoeslF.GoereciY.GerhardA.SchweitzerF.SchroederM.et al (2023). Association of cerebrospinal fluid brain-binding autoantibodies with cognitive impairment in post-COVID-19 syndrome. Brain Behav. Immun.109, 139–143. 10.1016/j.bbi.2023.01.006
22
FronteraJ. A.GuekhtA.AllegriR. F.AshrafM.BaykanB.CrivelliL.et al (2023). Evaluation and treatment approaches for neurological post-acute sequelae of COVID-19: a consensus statement and scoping review from the global COVID-19 neuro research coalition. J. Neurol. Sci.454, 120827. 10.1016/j.jns.2023.120827
23
GangJ.WangH.XueX.ZhangS. (2022). Microbiota and COVID-19: long-term and complex influencing factors. Front. Microbiol.13, 963488. 10.3389/fmicb.2022.963488
24
Garcia-SanchezC.CalabriaM.GrundenN.PonsC.ArroyoJ. A.Gomez-AnsonB.et al (2022). Neuropsychological deficits in patients with cognitive complaints after COVID-19. Brain Behav.12 (3), e2508. 10.1002/brb3.2508
25
GargouriB.CarstensenJ.BhatiaH. S.HuellM.DietzG. P. H.FiebichB. L. (2018). Anti-neuroinflammatory effects of Ginkgo biloba extract EGb761 in LPS-activated primary microglial cells. Phytomedicine44, 45–55. 10.1016/j.phymed.2018.04.009
26
GauthierS.SchlaefkeS. (2014). Efficacy and tolerability of Ginkgo biloba extract EGb 761® in dementia: a systematic review and meta-analysis of randomized placebo-controlled trials. Clin. Interv. Aging9, 2065–2077. 10.2147/CIA.S72728
27
GavrilovaS. I.PreussU. W.WongJ. W.HoerrR.KaschelR.BachinskayaN.et al (2014). Efficacy and safety of Ginkgo biloba extract EGb 761 in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial. Int. J. Geriatr. Psychiatry29 (10), 1087–1095. 10.1002/gps.4103
28
Grass-KapankeB.BusmaneA.LasmanisA.HoerrR.KaschelR. (2011). Effects of ginkgo biloba special extract EGb 761&#174; in very mild cognitive impairment (vMCI). Neurosci. Med.2 (01), 48–56. 10.4236/nm.2011.21007
29
GuedjE.CampionJ. Y.DudouetP.KaphanE.BregeonF.Tissot-DupontH.et al (2021). (18)F-FDG brain PET hypometabolism in patients with long COVID. Eur. J. Nucl. Med. Mol. Imaging48 (9), 2823–2833. 10.1007/s00259-021-05215-4
30
HadadR.KhouryJ.StangerC.FisherT.SchneerS.Ben-HayunR.et al (2022). Cognitive dysfunction following COVID-19 infection. J. Neurovirol28 (3), 430–437. 10.1007/s13365-022-01079-y
31
HausswirthC.SchmitC.RougierY.CosteA. (2023). Positive impacts of a four-week neuro-meditation program on cognitive function in post-acute sequelae of COVID-19 patients: a randomized controlled trial. Int. J. Environ. Res. Public Health20 (2), 1361. 10.3390/ijerph20021361
32
HegnaE.RackiV.HeroM.PapicE.RozmaricG.RadovicK.et al (2023). Post-COVID-19 syndrome in neurology patients: a single center experience. Pathogens12 (6), 796. 10.3390/pathogens12060796
33
Jimeno-AlmazanA.Buendia-RomeroA.Martinez-CavaA.Franco-LopezF.Sanchez-AlcarazB. J.Courel-IbanezJ.et al (2023). Effects of a concurrent training, respiratory muscle exercise, and self-management recommendations on recovery from post-COVID-19 conditions: the RECOVE trial. J. Appl. Physiol.134 (1), 95–104. 10.1152/japplphysiol.00489.2022
34
KoczullaA. R.AnkermannT.BehrendsU.BerlitP.BernerR.BöingS.et al (2022). AWMF S1-leitlinie long/post-COVID (S1 guideline long/post-COVID). Available at: https://register.awmf.org/de/leitlinien/detail/020-027 (Accessed August, 2023).
35
KuchlerT.GunthnerR.RibeiroA.HausingerR.StreeseL.WohnlA.et al (2023). Persistent endothelial dysfunction in post-COVID-19 syndrome and its associations with symptom severity and chronic inflammation. Angiogenesis26, 547–563. 10.1007/s10456-023-09885-6
36
KupferschmittA.EtzrodtF.KleinschmidtJ.KollnerV. (2023). Not only multimodal, but also interdisciplinary: a concept for interdisciplinary cooperation in the rehabilitation of post-COVID syndrome. Psychother. Psychosom. Med. Psychol.73 (1), 34–41. 10.1055/a-1838-3055
37
LauriaA.CarfiA.BenvenutoF.BramatoG.CiciarelloF.RocchiS.et al (2022). Neuropsychological measures of long COVID-19 fog in older subjects. Clin. Geriatr. Med.38 (3), 593–603. 10.1016/j.cger.2022.05.003
38
LengA.ShahM.AhmadS. A.PremrajL.WildiK.Li BassiG.et al (2023). Pathogenesis underlying neurological manifestations of long COVID syndrome and potential therapeutics. Cells12 (5), 816. 10.3390/cells12050816
39
LudwigB.DeckertM.KrajncN.KeritamO.MacherS.BstehG.et al (2023). Reported neurological symptoms after severe acute respiratory syndrome coronavirus type 2 infection: a systematic diagnostic approach. Eur. J. Neurol.30 (9), 2713–2725. 10.1111/ene.15923
40
LynchS.FerrandoS. J.DornbushR.ShaharS.SmileyA.KlepaczL. (2022). Screening for brain fog: is the montreal cognitive assessment an effective screening tool for neurocognitive complaints post-COVID-19?Gen. Hosp. Psychiatry78, 80–86. 10.1016/j.genhosppsych.2022.07.013
41
MagnavitaN.ArnesanoG.Di PrinzioR. R.GasbarriM.MeragliaI.MerellaM.et al (2023). Post-COVID symptoms in occupational cohorts: effects on health and work ability. Int. J. Environ. Res. Public Health20 (9), 5638. 10.3390/ijerph20095638
42
MajidiN.BahadoriE.ShekariS.GholamalizadehM.TajadodS.AjamiM.et al (2022). Effects of supplementation with low-dose group B vitamins on clinical and biochemical parameters in critically ill patients with COVID-19: a randomized clinical trial. Expert Rev. Anti Infect. Ther., 1–7. 10.1080/14787210.2022.2125867
43
ManganottiP.MicheluttiM.FurlanisG.DeodatoM.Buoite StellaA. (2023). Deficient GABABergic and glutamatergic excitability in the motor cortex of patients with long-COVID and cognitive impairment. Clin. Neurophysiol.151, 83–91. 10.1016/j.clinph.2023.04.010
44
Matias-GuiuJ. A.HerreraE.Gonzalez-NostiM.KrishnanK.Delgado-AlonsoC.Diez-CirardaM.et al (2023). Development of criteria for cognitive dysfunction in post-COVID syndrome: the IC-CoDi-COVID approach. Psychiatry Res.319, 115006. 10.1016/j.psychres.2022.115006
45
MinaY.Enose-AkahataY.HammoudD. A.VideckisA. J.NarpalaS. R.O'ConnellS. E.et al (2023). Deep phenotyping of neurologic postacute sequelae of SARS-CoV-2 infection. Neurol. Neuroimmunol. Neuroinflamm10 (4), e200097. 10.1212/NXI.0000000000200097
46
Mohamed HusseinA. A. R.GalalI.AminM. T.MoshnibA. A.MakhloufN. A.MakhloufH. A.et al (2022). Prevalence of vitamin D deficiency among patients attending Post COVID-19 follow-up clinic: a cross-sectional study. Eur. Rev. Med. Pharmacol. Sci.26 (8), 3038–3045. 10.26355/eurrev_202204_28635
47
MomtazmaneshS.AnsariS.IzadiZ.ShobeiriP.VatankhahV.SeifiA.et al (2023). Effect of famotidine on cognitive and behavioral dysfunctions induced in post-COVID-19 infection: a randomized, double-blind, and placebo-controlled study. J. Psychosom. Res.172, 111389. 10.1016/j.jpsychores.2023.111389
48
MonjeM.IwasakiA. (2022). The neurobiology of long COVID. Neuron110 (21), 3484–3496. 10.1016/j.neuron.2022.10.006
49
MuellerJ. K.MullerW. E. (2024). Multi-target drugs for the treatment of cognitive impairment and fatigue in post-COVID syndrome: focus on Ginkgo biloba and Rhodiola rosea. J. Neural Transm. (Vienna)131 (3), 203–212. 10.1007/s00702-024-02749-3
50
MullerL.Di BenedettoS. (2023). Aged brain and neuroimmune responses to COVID-19: post-acute sequelae and modulatory effects of behavioral and nutritional interventions. Immun. Ageing20 (1), 17. 10.1186/s12979-023-00341-z
51
NasreddineZ. S.PhillipsN. A.BedirianV.CharbonneauS.WhiteheadV.CollinI.et al (2005). The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J. Am. Geriatr. Soc.53 (4), 695–699. 10.1111/j.1532-5415.2005.53221.x
52
NavisA. (2023). A review of neurological symptoms in long COVID and clinical management. Semin. Neurol.43 (2), 286–296. 10.1055/s-0043-1767781
53
NicotraA.MasseriniF.CalcaterraF.Di VitoC.DonedduP. E.PomatiS.et al (2023). What do we mean by long-COVID? A scoping review of the cognitive sequelae of SARS-CoV-2 infection. Eur. J. Neurol.30, 3968–3978. 10.1111/ene.16027
54
NodaY.SatoA.ShichiM.SatoA.FujiiK.IwasaM.et al (2023). Real world research on transcranial magnetic stimulation treatment strategies for neuropsychiatric symptoms with long-COVID in Japan. Asian J. Psychiatr.81, 103438. 10.1016/j.ajp.2022.103438
55
OstergaardL. (2021). SARS CoV-2 related microvascular damage and symptoms during and after COVID-19: consequences of capillary transit-time changes, tissue hypoxia and inflammation. Physiol. Rep.9 (3), e14726. 10.14814/phy2.14726
56
PalladiniM.BraviB.ColomboF.CaselaniE.Di PasquasioC.D'OrsiG.et al (2023). Cognitive remediation therapy for post-acute persistent cognitive deficits in COVID-19 survivors: a proof-of-concept study. Neuropsychol. Rehabil.33 (7), 1207–1224. 10.1080/09602011.2022.2075016
57
PavlidouE.PouliosE.PapadopoulouS. K.FasoulasA.DakanalisA.GiaginisC. (2024). Clinical evidence on the potential beneficial effects of diet and dietary supplements against COVID-19 infection risk and symptoms' severity. Med. Sci. (Basel)12 (1), 11. 10.3390/medsci12010011
58
PierreS. V.LesnikP.MoreauM.BonelloL.Droy-LefaixM. T.SennouneS.et al (2008). The standardized Ginkgo biloba extract Egb-761 protects vascular endothelium exposed to oxidized low density lipoproteins. Cell Mol. Biol. (Noisy-le-grand)54, OL1032–1042.
59
PooladgarP.SakhabakhshM.Soleiman-MeigooniS.TaghvaA.NasiriM.DarazamI. A. (2023). The effect of donepezil hydrochloride on post-COVID memory impairment: a randomized controlled trial. J. Clin. Neurosci.118, 168–174. 10.1016/j.jocn.2023.09.005
60
ProalA. D.VanElzakkerM. B. (2021). Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front. Microbiol.12, 698169. 10.3389/fmicb.2021.698169
61
RabadyS.HoffmannK.AignerM.AltenbergerJ.BroseM.CostaU.et al (2023). S1 guidelines for the management of postviral conditions using the example of post-COVID-19. Wien Klin. Wochenschr135 (4), 525–598. 10.1007/s00508-023-02242-z
62
RabaiottiP.CiraciC.DonelliD.OggioniC.RizziB.SaviF.et al (2023). Effects of multidisciplinary rehabilitation enhanced with neuropsychological treatment on post-acute SARS-CoV-2 cognitive impairment (brain fog): an observational study. Brain Sci.13 (5), 791. 10.3390/brainsci13050791
63
SchildA. K.GoereciY.ScharfenbergD.KleinK.LullingJ.MeiberthD.et al (2023). Multidomain cognitive impairment in non-hospitalized patients with the post-COVID-19 syndrome: results from a prospective monocentric cohort. J. Neurol.270 (3), 1215–1223. 10.1007/s00415-022-11444-w
64
SchmachtenbergT.MullerF.KranzJ.DragaqinaA.WegenerG.KonigsG.et al (2023). How do long COVID patients perceive their current life situation and occupational perspective? Results of a qualitative interview study in Germany. Front. Public Health11, 1155193. 10.3389/fpubh.2023.1155193
65
SchrimpfA.BraesigkA.LippmannS.BleckwennM. (2022). Management and treatment of long COVID symptoms in general practices: an online-based survey. Front. Public Health10, 937100. 10.3389/fpubh.2022.937100
66
SchulzM.HoerrR.MuellerH. (2018). 46th ESCP symposium on clinical pharmacy "Science meets practice: towards evidence-based clinical pharmacy services", Heidelberg, Germany, October 9th-11th, 2017. Int. J. Clin. Pharm.40 (1), 203–317. 10.1007/s11096-017-0565-9
67
Serrano-CastroP. J.Garzon-MaldonadoF. J.Casado-NaranjoI.Ollero-OrtizA.Minguez-CastellanosA.Iglesias-EspinosaM.et al (2022). The cognitive and psychiatric subacute impairment in severe Covid-19. Sci. Rep.12 (1), 3563. 10.1038/s41598-022-07559-9
68
ShanleyJ. E.ValencianoA. F.TimmonsG.MinerA. E.KakarlaV.RempeT.et al (2022). Longitudinal evaluation of neurologic-post acute sequelae SARS-CoV-2 infection symptoms. Ann. Clin. Transl. Neurol.9 (7), 995–1010. 10.1002/acn3.51578
69
SherifZ. A.GomezC. R.ConnorsT. J.HenrichT. J.ReevesW. B.ForceR. M. P. T. (2023). Pathogenic mechanisms of post-acute sequelae of SARS-CoV-2 infection (PASC). Elife12, e86002. 10.7554/eLife.86002
70
Siso-AlmirallA.Brito-ZeronP.Conangla FerrinL.KostovB.Moragas MorenoA.MestresJ.et al (2021). Long covid-19: proposed primary care clinical guidelines for diagnosis and disease management. Int. J. Environ. Res. Public Health18 (8), 4350. 10.3390/ijerph18084350
71
SongE.ZhangC.IsraelowB.Lu-CulliganA.PradoA. V.SkriabineS.et al (2021). Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med.218 (3), e20202135. 10.1084/jem.20202135
72
SuY.YuanD.ChenD. G.NgR. H.WangK.ChoiJ.et al (2022). Multiple early factors anticipate post-acute COVID-19 sequelae. Cell185 (5), 881–895.e20. 10.1016/j.cell.2022.01.014
73
SykesD. L.HoldsworthL.JawadN.GunasekeraP.MoriceA. H.CrooksM. G. (2021). Post-COVID-19 symptom burden: what is long-COVID and how should we manage it?Lung199 (2), 113–119. 10.1007/s00408-021-00423-z
74
TaruffiL.MuccioliL.MitoloM.FerriL.DescovichC.MazzoniS.et al (2023). Neurological manifestations of long COVID: a single-center one-year experience. Neuropsychiatr. Dis. Treat.19, 311–319. 10.2147/NDT.S387501
75
TeixidoL.AndreevaE.GartmannJ.LemhoferC.SturmC.GutenbrunnerC. (2023). Outpatient rehabilitative care for patients with Long-COVID - a guideline-based clinical practice guideline. Laryngorhinootologie102 (7), 521–532. 10.1055/a-1985-0450
76
TosatoM.CiciarelloF.ZazzaraM. B.PaisC.SaveraG.PiccaA.et al (2022). Nutraceuticals and dietary supplements for older adults with long COVID-19. Clin. Geriatr. Med.38 (3), 565–591. 10.1016/j.cger.2022.04.004
77
ViethR. (2022). Critique of public health guidance for vitamin D and sun exposure in the context of cancer and COVID-19. Anticancer Res.42 (10), 5027–5034. 10.21873/anticanres.16011
78
VollbrachtC.KraftK. (2021). Feasibility of vitamin C in the treatment of post viral fatigue with focus on long COVID, based on a systematic review of IV vitamin C on fatigue. Nutrients13 (4), 1154. 10.3390/nu13041154
79
WalkerS.GoodfellowH.PookarnjanamorakotP.MurrayE.BindmanJ.BlandfordA.et al (2023). Impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome: a cross-sectional observational study. BMJ Open13 (6), e069217. 10.1136/bmjopen-2022-069217
80
World Health Organization (2021). A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Geneva: World Health Organization.
81
YangF.ZhaoH.LiuH.WuX.LiY. (2021). Manifestations and mechanisms of central nervous system damage caused by SARS-CoV-2. Brain Res. Bull.177, 155–163. 10.1016/j.brainresbull.2021.09.015
82
ZaaC. A.EspitiaC.Reyes-BarreraK. L.AnZ.Velasco-VelazquezM. A. (2023). Neuroprotective agents with therapeutic potential for COVID-19. Biomolecules13 (11), 1585. 10.3390/biom13111585
83
ZhangC.WangD. F.ZhangZ.HanD.YangK. (2017). EGb 761 protects cardiac microvascular endothelial cells against hypoxia/reoxygenation injury and exerts inhibitory effect on the ATM pathway. J. Microbiol. Biotechnol.27 (3), 584–590. 10.4014/jmb.1611.11024
84
ZifkoU. A.YacobM.BraunB. J.DietzG. P. H. (2022). Alleviation of post-COVID-19 cognitive deficits by treatment with EGb 761®: a case series. Am. J. Case Rep.23, e937094. 10.12659/AJCR.937094
Summary
Keywords
post-acute covid, long-COVID syndrome, cognitive impairment, management, Ginkgo biloba extract, EGb 761®
Citation
Zifko U, Guendling K, Seet R and Kasper S (2024) Management of cognitive impairment associated with post-COVID-19 syndrome: recommendations for primary care. Front. Pharmacol. 15:1338235. doi: 10.3389/fphar.2024.1338235
Received
14 November 2023
Accepted
22 March 2024
Published
22 April 2024
Volume
15 - 2024
Edited by
Thomas Brendler, University of Johannesburg, South Africa
Reviewed by
Priscilla Kolibea Mante, Kwame Nkrumah University of Science and Technology, Ghana
Zhiyong Wang, China Academy of Chinese Medical Sciences, China
Updates
Copyright
© 2024 Zifko, Guendling, Seet and Kasper.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Udo Zifko, ordination@zifko.at
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.